Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06156410 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
A Phase 1 study of Osteosarcoma and Ewing Sarcoma, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT06156410 is a Phase 1 study of Osteosarcoma and Ewing Sarcoma that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 30 participants, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06156410, a Phase 1 study of Osteosarcoma and Ewing Sarcoma, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (4)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- University of Pennsylvania - Philadelphia
California
- University of California San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-10-24 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06156410
The ClinicalTrials.gov registry entry for NCT06156410 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 301-participant average among 46 other Osteosarcoma trials with a reported enrollment target (90% lower). The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT06156410 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06156410 about?
NCT06156410 is a clinical study titled "Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas". The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
What is the current status of trial NCT06156410?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-10-24. Estimated completion is 2028-11.
What conditions does trial NCT06156410 study?
This clinical trial studies the following conditions: Osteosarcoma, Ewing Sarcoma, Sarcomas.
What interventions are being tested in trial NCT06156410?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT06156410?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06156410 being conducted?
This trial has 4 study locations across California, Colorado, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Losartan + Sunitinib in Treatment of Osteosarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.